Village Farms(US:VFF)2026-03-12 20:17Market Position and Expansion - Village Farms maintained a top five overall market share position in Canada and held the number one position in dried flower as of February 2026, despite planned reductions in sales of lower-margin SKUs [412]. - International export sales increased 517% year-over-year, driven by strong demand in Germany and steady performance across other international markets [417]. - The expansion of cultivation capacity in the Delta 2 greenhouse is expected to yield an incremental 40 metric tons of annualized cannabis production, expanding capacity by approximately 33% once completed [412]. - The Phase II facility in Groningen is nearing completion and is expected to quintuple total annualized production to approximately 10,000 kilograms when fully operational [417]. - The Company believes it remains the largest exporter of medical cannabis to Europe, with three of the top five leading cultivars in Germany [417]. - The acquisition of the remaining 15% equity ownership interest in Leli Holland was completed in September 2024, allowing the Company to cultivate and distribute cannabis legally in the Netherlands [393]. - The Company's application for a Texas medicinal marijuana license remains under review, with DPS required to award a minimum of three new licenses on or before April 1, 2026 [417]. Financial Performance - Sales for the year ended December 31, 2025 increased by $20,030, or approximately 10%, to $215,937 from $195,907 for the year ended December 31, 2024 [422]. - Cost of sales for the year ended December 31, 2025 decreased by $21,851, or 15%, to $128,255 from $150,106 for the year ended December 31, 2024 [423]. - Gross profit for the year ended December 31, 2025 increased by $41,881, or 91%, to $87,682 from $45,801 for the year ended December 31, 2024 [424]. - Selling, general and administrative expenses for the year ended December 31, 2025 decreased by $1,455 to $60,293, or 28% of sales, from $61,748, or 32% of sales, for the year ended December 31, 2024 [425]. - Net income attributable to Village Farms International, Inc. shareholders for the year ended December 31, 2025 was $32,441, compared to a loss of $35,851 for the year ended December 31, 2024, an increase of $68,292 [436]. - Adjusted EBITDA from continuing operations for the year ended December 31, 2025 increased by $42,478 to $49,852 from $7,374 for the year ended December 31, 2024 [437]. - Income before taxes for the year ended December 31, 2025 was $31,359 compared to a loss of $29,604 for the year ended December 31, 2024, an increase of $60,963 [432]. - Other income for the year ended December 31, 2025 was $4,173 compared to $4,015 for the year ended December 31, 2024 [430]. - The net income (loss) including non-controlling interests for the year ended December 31, 2025, was $32,105 [453]. - Basic income (loss) per share from continuing operations for the year ended December 31, 2025, was $0.01 [453]. - Diluted income (loss) per share for the year ended December 31, 2025, was $0.10 [453]. Cost Management - The company incurred excise duties of $59,950 (C$83,744) for the year ended December 31, 2025, representing 38% of gross branded sales, a decrease from 39% in 2024, due to lower kilograms sold in the branded channel [461]. - Selling, general and administrative expenses for the year ended December 31, 2025 increased by $844, or 2%, to $34,872, representing 21% of net sales, compared to 23% in 2024 [467]. - U.S. Cannabis selling, general and administrative expenses for the year ended December 31, 2025 decreased by $2,405 to $9,585, or 66% of sales, from $11,990, or 69% of sales, for the year ended December 31, 2024 [489]. - Share-based compensation expenses were $1,741 thousand in 2025, down from $3,747 thousand in 2024, reflecting a potential cost management strategy [541]. Operational Challenges - The Canadian Cannabis segment continues to face challenges with excise taxes, which remain the largest cost in the branded adult-use market, impacting overall profitability [461]. - U.S. Cannabis net sales for the year ended December 31, 2025 decreased by $2,951, or 17%, to $14,439 from $17,390 for the year ended December 31, 2024 [485]. - U.S. Cannabis gross profit for the year ended December 31, 2025 was $9,023, representing a 63% gross margin, compared to $11,035 and a 66% gross margin for the year ended December 31, 2024 [488]. - U.S. Cannabis net loss for the year ended December 31, 2025 was $782 compared to a loss of $13,333 for the year ended December 31, 2024, showing significant improvement [491]. - U.S. Cannabis Adjusted EBITDA from continuing operations for the year ended December 31, 2025 was ($288) compared to ($672) for the year ended December 31, 2024, indicating improved operational efficiency [492]. Asset Management - The company recorded goodwill and intangible impairments of $11,939 thousand in 2024 and $14,020 thousand in 2023, which were not present in 2025, suggesting improved asset management [541]. - The company reported a net income from continuing operations of $20,988 thousand for the year ended December 31, 2025, compared to a net loss of $27,942 thousand in 2024 [543]. - The cannabis segment in Canada generated a net income of $26,241 for 2025, a significant improvement from a loss of $2,814 in 2024 [543]. - The corporate segment reported a net loss of $8,761 in 2025, compared to a loss of $7,490 in 2024, highlighting ongoing challenges [543]. Cash Flow and Financing - As of December 31, 2025, the company had $86,252 in cash and cash equivalents, significantly up from $24,631 as of December 31, 2024 [520]. - Cash flow from operating activities for the year ended December 31, 2025, was $58,112, significantly up from $13,728 in 2024 [534]. - Cash used in investing activities for 2025 was $18,614, primarily due to capital expenditures of $11,624 for the Cannabis Netherlands Phase II facility [535]. - Financing activities for 2025 resulted in a net cash outflow of $6,351, including net repayments on borrowings of $7,865 [536]. - The outstanding amount of the Pure Sunfarms Term Loan Facility was $17,799 as of December 31, 2025, with quarterly repayments of C$1.0 million [528]. - The Company entered into a secured credit facility with a Canadian bank on April 17, 2025, with an aggregate borrowing capacity of C$37.4 million, including a C$10.0 million revolving credit facility and a C$27.4 million term loan [527]. Future Outlook - The company plans to focus on market expansion and new product development in the upcoming fiscal year to improve financial performance [454]. - The company anticipates a compound annual revenue growth rate of 7.5% from 2025 to 2029 for its Canadian Cannabis segment [553]. - The company anticipates an average revenue growth rate of 8% over the next 6 years, followed by a terminal growth rate of 4.1% [569]. - The company plans to increase its interest in Rose LifeScience to 80% starting April 1, 2024, and to 100% in Leli beginning September 23, 2024, indicating a strategy for market expansion [542].